The Apixaban market growth is fueled by rising cardiovascular disease prevalence, increasing geriatric population, and preference for oral anticoagulants over injectable alternatives. Apixaban’s advantages, such as predictable pharmacokinetics, reduced monitoring, and lower risk of major bleeding, contribute to its rapid adoption. Health awareness campaigns and patient education...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek